ProCE Banner Activity

DeFi: Subgroup Analysis of Nirogacestat Efficacy in Patients With Desmoid Tumors and Poor Prognostic Factors

Conference Coverage
Slideset

Post hoc analyses of the phase III DeFi trial suggest that patient subgroups with desmoid tumors and poor prognostic factors experienced improved PFS, ORR, and QoL with nirogacestat treatment.

Released: December 04, 2024

Expiration: December 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics, Inc.